Guardian Pharmacy Services Earnings Call Transcripts
Fiscal Year 2026
-
Strong Q4 momentum was driven by vaccine clinics, acquisitions, and operational optimization. Guidance was raised on robust vaccine performance, with IRA headwinds expected to diminish. Growth is supported by demographic trends, M&A, and innovative clinical programs, while strong cash flow enables continued expansion.
-
A leading assisted living pharmacy provider is leveraging organic growth, disciplined M&A, and a tech-enabled service model to expand its 13% market share. Strong financials, high adoption rates, and proactive regulatory engagement position it for continued growth amid favorable demographic trends.
-
A leading long-term care pharmacy provider for assisted living facilities, the company leverages technology, data analytics, and a disciplined growth strategy to expand its 13% market share. Despite regulatory headwinds from the Inflation Reduction Act, it projects continued EBITDA growth and strong cash flow, supported by organic expansion and targeted M&A.
Fiscal Year 2025
-
Q4 and full-year 2025 results exceeded expectations, with 18% revenue growth and 27% adjusted EBITDA growth year-over-year. Raised 2026 EBITDA guidance to $120–$124 million, maintaining strong cash flow and robust M&A pipeline amid industry changes.
-
The conference highlighted a strategy focused on assisted living, leveraging clinician-led, tech-enabled services and advanced analytics to drive organic and inorganic growth. Regulatory headwinds from the IRA are being offset, and expansion into adjacent markets like PACE and hospice is underway. Key profitability improvements stem from operational integration and service innovation.
-
Achieved 20% revenue growth and 19% adjusted EBITDA growth year-over-year, raising full-year guidance for both metrics. Recent acquisitions and organic growth drove results, with steady margins and strong cash generation supporting ongoing expansion.
-
A specialized pharmacy provider for assisted living is leveraging its market leadership, scale, and tech-enabled services to drive double-digit growth through organic expansion and M&A. Strategic focus on reimbursement, regulatory mitigation, and adjacent markets supports a strong financial profile and differentiates it from legacy competitors.
-
Q2 2025 saw double-digit growth in revenue, resident count, and adjusted EBITDA, with strong organic and acquisition-driven expansion. Guidance for full-year revenue and EBITDA was raised, while policy risks from the IRA and PBM negotiations are being proactively managed.
-
Q1 2025 saw 20% revenue growth and 16% higher Adjusted EBITDA, driven by organic expansion and acquisitions. Guidance was raised to the upper end of the revenue range, with integration costs impacting Q1 but future margin improvements expected as new pharmacies scale.
-
A leading institutional pharmacy in the assisted living segment reported strong Q4 and full-year growth, driven by organic expansion, M&A, and tech-enabled services. With 12% market share and a robust employee ownership culture, it projects continued growth and margin improvement in 2025.
Fiscal Year 2024
-
Q4 and full-year 2024 saw double-digit revenue and EBITDA growth, driven by organic expansion and acquisitions. Guidance for 2025 projects continued high single-digit organic growth, steady margins, and robust M&A activity, with proactive steps to address IRA-related risks.
-
A leading long-term care pharmacy provider is leveraging a focused assisted living strategy, robust technology, and disciplined M&A to drive double-digit growth. Legislative and commercial efforts are underway to address IRA-related reimbursement headwinds, while new analytics tools and market expansion initiatives support continued value creation.
-
Third quarter revenue rose 20% year-over-year to $314 million, with adjusted EBITDA also up 20%. Resident count increased 12%, and the Heartland acquisition is progressing well. Guidance for 2024 projects $1.205–$1.215 billion in revenue and $86.5–$87 million in adjusted EBITDA.